Alexion Pharmaceuticals Inc. continues to reshape its top-level management after the company was hit by an internal investigation into its sales practices.
Alexion will start a search for a new Chief Financial Officer after current CFO Dave Anderson announced he will resign at the end of August. Anderson had joined the company in December after more than a decade as CFO at Honeywell International Inc. He had replaced Vikas Sinha, who resigned last year along with CEO David Hallal during the sales practices investigation.
Ludwig Hantson was named named Alexion’s chief executive in March.
The company has appointed Brian Goff as Chief Commercial Officer, effective June 1. Goff is a veteran biopharmaceutical executive with more than 25 years of experience at companies including Neurovance, Inc., Baxalta, Inc., Baxter, Novartis and Johnson & Johnson.
Earlier this year, Alexion found that some of its senior management staff had pressured employees to get customers to order its flagship drug Soliris earlier than needed to meet financial targets
Source: RTT News
The United Arab Emirates (UAE) Ministry of Health and Prevention (MoHAP) has established a partnership with Novo Nordisk Pharma Gulf focusing on the creation of a national scientific guide for obesity management and weight control. The collaboration also aims to enhance public awareness of cardiovascular diseases and their complications.
Pharma giant Eli Lilly is teaming up with Haya Therapeutics in a $1bn deal to find multiple regulatory-genome-derived RNA-based drug targets, as it eyes up new targets in obesity. Under the deal, the companies will use Haya’s proprietary regulatory genome discovery platform to identify and validate long non-coding RNA (lncRNA) targets for developing potential treatments for obesity and related metabolic disorders.
The sale includes custom formulation and contract manufacturing capabilities for the nutrition market from the production facilities in New Jersey and Utah in the United States, and Tamaulipas, Mexico. Financial terms of the transaction were not disclosed.
